Form 4: Passage BIO Director Acquires Stock Options

Thomas Richard Kassberg, a Director at Passage BIO, Inc., acquired 10,539 stock options on May 19, 2026, with an exercise price of $5.08.

Summary

• Thomas Richard Kassberg, a Director at Passage BIO, Inc. (PASG), acquired 10,539 stock options on May 19, 2026.
• The stock options have an exercise price of $5.08 per share.
• These options are exercisable and will vest in full on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2027 Annual Meeting of Stockholders, provided Kassberg remains in continuous service.
• Following this transaction, Kassberg beneficially owns 10,539 shares of common stock through these options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director stock option grant, indicating continued engagement and potential long-term alignment, but without immediate financial impact or new strategic information.

Positives

• Director acquisition of stock options signals confidence in the company's future prospects.
• The vesting schedule aligns the director's incentives with long-term company performance.

Risks

• The value of the stock options is subject to the future performance of Passage BIO's stock price.
• The vesting of options is contingent on the reporting person's continuous service to the issuer.

Future Outlook

The stock options are set to vest on the earlier of the one-year anniversary of the grant date or the issuer's 2027 Annual Meeting of Stockholders, contingent on continuous service.

Industry Context

StockSavvy.ai notes that director stock option grants are a common form of executive compensation in the biotechnology sector, intended to align leadership interests with shareholder value creation and incentivize long-term growth.

Stakeholder Impact

• Shareholders: The grant of options to a director can be viewed positively as it aligns management's interests with long-term stock performance. However, the dilutive effect of future share issuance upon exercise should be considered.
• Employees: Standard compensation practice, unlikely to have a direct impact.
• Creditors: No direct impact.
• Suppliers: No direct impact.

Next Steps

• Continuous service by Thomas Richard Kassberg to Passage BIO, Inc.

Key Dates

Keywords

stock options, insider trading, Passage BIO, director compensation, equity award, PASG